John Hsiao
A5036507830- Schizophrenia research and treatment
- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Antenna Design and Optimization
- Mental Health and Psychiatry
- Treatment of Major Depression
- Bipolar Disorder and Treatment
- Neurotransmitter Receptor Influence on Behavior
- Advanced Neuroimaging Techniques and Applications
- Diet and metabolism studies
- Bioinformatics and Genomic Networks
- Genetic Associations and Epidemiology
- Electroconvulsive Therapy Studies
- Health Systems, Economic Evaluations, Quality of Life
- Amyotrophic Lateral Sclerosis Research
- Stress Responses and Cortisol
- Radar Systems and Signal Processing
- Neuroscience and Neuropharmacology Research
- Advanced Antenna and Metasurface Technologies
- Parkinson's Disease Mechanisms and Treatments
- Antibiotics Pharmacokinetics and Efficacy
- Tryptophan and brain disorders
- Metabolomics and Mass Spectrometry Studies
- Obsessive-Compulsive Spectrum Disorders
Alzheimer’s Disease Neuroimaging Initiative
2021-2025
National Institute on Aging
2015-2024
National Institutes of Health
2005-2022
Institute on Aging
2015-2016
Duke University
2011
University of Southern California
2011
Neurobehavioral Systems
2011
University of California, Los Angeles
2011
Icahn School of Medicine at Mount Sinai
2011
Banner Health
2011
The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that older agents has been incompletely addressed, though newer are currently used far more commonly. We a first-generation antipsychotic, perphenazine, several in double-blind study.
Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits uncertain concerns about safety have emerged. We assessed the effectiveness of atypical outpatients disease.In this 42-site, double-blind, placebo-controlled trial, 421 disease or were randomly assigned receive olanzapine (mean dose, 5.5 mg per day), quetiapine 56.5 risperidone 1.0 placebo. Doses adjusted as needed, followed...
Abstract Multifactorial mechanisms underlying late-onset Alzheimer’s disease (LOAD) are poorly characterized from an integrative perspective. Here spatiotemporal alterations in brain amyloid-β deposition, metabolism, vascular, functional activity at rest, structural properties, cognitive integrity and peripheral proteins levels relation to LOAD progression. We analyse over 7,700 images tens of plasma cerebrospinal fluid biomarkers the Disease Neuroimaging Initiative (ADNI). Through a...
Objective: When a schizophrenia patient has an inadequate response to treatment with antipsychotic drug, it is unclear what other switch and when use clozapine. In this study, the authors compared switching clozapine another atypical in patients who had discontinued newer context of Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation. Method: Ninety-nine olanzapine, quetiapine, risperidone, or ziprasidone phase 1 1B trials, primarily because efficacy, were...
OBJECTIVE: There is growing interest in identifying and surmounting barriers to employment for people with schizophrenia. The authors examined factors associated participation competitive or other vocational activities a large group of patients schizophrenia who participated the Clinical Antipsychotic Trials Intervention Effectiveness (CATIE) study, multisite clinical trial comparing effects first- second-generation antipsychotics. METHOD: Baseline data on more than 1,400 diagnosis were...
Background: In the treatment of schizophrenia, changing antipsychotics is common when one suboptimally effective, but relative effectiveness drugs used in this strategy unknown. This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone patients who had just discontinued a different atypical antipsychotic. Method: Subjects with schizophrenia (N=444) antipsychotic randomly assigned during phase 1 Clinical Antipsychotic Trials Intervention Effectiveness...
Abstract Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by decline in cognitive functions with no validated modifying treatment. It critical for timely treatment to detect AD its earlier stage before clinical manifestation. Mild impairment (MCI) an intermediate between cognitively normal older adults and AD. To predict conversion from MCI probable AD, we applied deep learning approach, multimodal recurrent neural network. We developed integrative framework that...
Objective: The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer’s disease psychosis or agitated behavior. Method: Clinical Antipsychotic Trials Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) effectiveness included 421 outpatients agitated/aggressive Patients were assigned randomly to masked, flexible-dose treatment olanzapine, quetiapine, risperidone, placebo for up 36 weeks. could be reassigned a different...
There is considerable debate whether Alzheimer's disease (AD) originates in basal forebrain or entorhinal cortex. Here we examined longitudinal decreases and cortex grey matter volume were interdependent sequential. In a large cohort of age-matched older adults ranging from cognitively normal to AD, demonstrate that predicts degeneration. Models parallel degeneration origin received negligible support. We then integrated volumetric measures with an amyloid biomarker sensitive pre-symptomatic...
Abstract Brain iron elevation is implicated in Alzheimer’s disease (AD) pathogenesis, but the impact of on outcomes has not been previously explored a longitudinal study. Ferritin major storage protein body; by using cerebrospinal fluid (CSF) levels ferritin as an index, we whether brain status impacts Disease Neuroimaging Initiative (ADNI) cohort. We show that baseline CSF were negatively associated with cognitive performance over 7 years 91 cognitively normal, 144 mild impairment (MCI) and...
Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer's disease is unclear. authors assessed effects time treatment neuropsychological functioning during Clinical Antipsychotic Trials Intervention Effectiveness–Alzheimer's Disease study (CATIE-AD). Method: CATIE-AD included 421 outpatients psychosis or agitated/aggressive behavior who were randomly assigned to receive masked, flexible-dose risperidone, placebo....
Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its ability to monitor progression in AD remains unclear.To study potential longitudinal plasma p-tau181 measures assessing neurodegeneration and cognitive decline comparison neurofilament light chain (NfL), a disease-nonspecific marker neuronal injury.This cohort included data from Alzheimer's Disease Neuroimaging Initiative...
Background: In the treatment of schizophrenia, changing antipsychotics is common when one suboptimally effective, but relative effectiveness drugs used in this strategy unknown. This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone patients who had just discontinued a different atypical antipsychotic. Method: Subjects with schizophrenia (N=444) antipsychotic randomly assigned during phase 1 Clinical Antipsychotic Trials Intervention Effectiveness...
Objective: This study examined the relative effects of second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia. Method: Consenting were enrolled NIMH Clinical Antipsychotic Trials Intervention Effectiveness (CATIE) project. In phase 1, randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone for up 18 months. Clozapine was included who chose this pathway after...
BACKGROUND: Second-generation antipsychotics have largely replaced first-generation for the treatment of schizophrenia, but a large-scale cost/effectiveness analysis has not been attempted. Method: Patients with schizophrenia (N=1,493) were assigned to antipsychotic (perphenazine) or one four second-generation drugs (olanzapine, quetia-pine, risperidone, ziprasidone) and followed up 18 months. tardive dyskinesia prohibited from assignment perphenazine. could be reassigned at any time another...
With every issue of theArchives, the reader is inundated with psychiatric research: new treatments, biological abnormalities, diagnostic methods, diagnoses—the list seems endless. It difficult to conceive anyone, except, course, our dedicated Editor, who bothers read article in issue. Indeed, it would be a rare individual had time abstract. In current Mossman and Somoza<sup>1</sup>reexamine dexamethasone suppression test (DST) using statistical method that psychiatry, namely, receiver...
The relative effectiveness of newly started antipsychotic drugs for individuals with schizophrenia may depend on multiple factors, including each patient's previous treatment response and the reason a new medication trial. This randomized, double-blind study compared olanzapine, quetiapine, risperidone in patients who had just discontinued older perphenazine.Subjects (N=114) been randomly assigned to then perphenazine phase 1 Clinical Antipsychotic Trials Intervention Effectiveness (CATIE)...
To test the hypothesis that cortical and hippocampal volumes, measured in vivo from volumetric MRI (vMRI) scans, could be used to identify variant subtypes of Alzheimer disease (AD) prospectively predict rate clinical decline.Amyloid-positive participants with AD Alzheimer's Disease Neuroimaging Initiative (ADNI) 1 ADNI2 baseline scans (n = 229) 2-year follow-up 100) were included. (hippocampal sparing [HpSpMRI], limbic predominant [LPMRI], typical [tADMRI]) defined according an algorithm...
A lthough studies of secondgeneration antipsychotics in schizophrenia have indicated that these drugs are comparable to the first-generation reducing psychotic symptoms and they produce few neurologic effects, with exception clozapine, evidence for their superior efficacy safety has been inconsistent (1-10).As a result dominant prescribing preferences second-generation over antipsychotics, despite greater cost, questions raised about clinical advantages cost-effectiveness antipsychotics.This...
Abstract Alzheimer’s disease (AD) is a leading cause of mortality in the elderly. While coding change APOE -ε4 key risk factor for late-onset AD and has been believed to be only locus, it does not fully explain effect conferred by locus. Here, we report identification causal variants PVRL2 APOC1 regions proximity define common haplotypes independent change. These are associated with changes AD-related endophenotypes including cognitive performance, altered expression its nearby genes human...